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2C-B) has recently emerged as a new psychoactive substance (NPS). It is 
most commonly consumed orally although there are indications that it 
might also be ingested by inhalation or ‘smoking’. Information about the 
stability of bk-2C-B when exposed to heat is unavailable and the potential 
for pyrolytic degradation and formation of unknown substances available 
for inhalation prompted an investigation using a simulated ‘meth pipe’ 
scenario. Twelve products following pyrolysis of bk-2C-B were detected and 
verified by organic synthesis of the corresponding standards. In addition, 
2-amino-1-(4-iodo-2,5-dimethoxyphenyl)ethanone hydrochloride (bk-2C-I) 
has been characterized for the first time and subjected to pyrolysis as well. 
Similar products were formed, which indicated that the replacement of the 
bromo with the iodo substituent did not affect the pyrolysis pattern under 
the conditions used. Two additional products were detected in the bk-2C-I 
pyrolates, namely 1-(2,5-dimethoxyphenyl)-ethanone and 1-iodo-4-
ethenyl-5-methoxyphenol.  The potential ingestion of pyrolysis products 
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2-Amino-1-(4-bromo-2,5-dimethoxyphenyl)ethanone hydrochloride (bk-2C-B) has recently 
emerged as a new psychoactive substance (NPS). It is most commonly consumed orally although 
there are indications that it might also be ingested by inhalation or ‘smoking’. Information about 
the stability of bk-2C-B when exposed to heat is unavailable and the potential for pyrolytic 
degradation and formation of unknown substances available for inhalation prompted an 
investigation using a simulated ‘meth pipe’ scenario. Twelve products following pyrolysis of bk-
2C-B were detected and verified by organic synthesis of the corresponding standards. In 
addition, 2-amino-1-(4-iodo-2,5-dimethoxyphenyl)ethanone hydrochloride (bk-2C-I) has been 
characterized for the first time and subjected to pyrolysis as well. Similar products were formed, 
which indicated that the replacement of the bromo with the iodo substituent did not affect the 
pyrolysis pattern under the conditions used. Two additional products were detected in the bk-2C-
I pyrolates, namely 1-(2,5-dimethoxyphenyl)-ethanone and 1-iodo-4-ethenyl-5-methoxyphenol.  
The potential ingestion of pyrolysis products with unknown toxicity adds an element of concern. 
 
INTRODUCTION   
Many ring-substituted phenethylamines show psychoactive and psychedelic effects in humans[1] 
and these are based on the now considered prototypical set of substances published in 
PIHKAL.[2] The extent of their control varies across the globe and depends on the nature of 
legislative control mechanisms that are in place. A number of phenethylamines not specifically 
controlled internationally or those exemplifying a development beyond the traditional PHKAL 
compounds[3] are sometimes captured under the term new psychoactive substances (NPS).[4] In 
the last decade, the number of unregulated psychoactive substances available for purchase via the 
Internet and high street shops has grown significantly, which created challenges to policy 
makers, health care professionals, law enforcement and researchers across disciplines.[5-7] 
One of the phenethylamine analogs emerging on the NPS market in more recent years was 2-
amino-1-(4-bromo-2,5-dimethoxyphenyl)ethanone hydrochloride (bk-2C-B) (Figure 1), the beta-
keto analog of the popular psychedelic 2-(4-bromo-2,5-dimethoxyphenyl)ethan-1-amine (2C-B). 
The detection of bk-2C-B on the European market was first reported to the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA) in December 2013[8] and it has since been 
detected in other European countries including e.g. Italy.[9] The synthesis of bk-2C-B was first 
published in 2004 where it served as an intermediate for the preparation of 2-(4-bromo-2,5-
dimethoxyphenyl)morpholine.[10] The synthesis and extensive analytical characterization of bk-
2C-B, verifying the identification of this substance obtained from a test purchase from an 
Internet vendor, was reported more recently. Furthermore, it was reported that bk-2C-B was 
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prone to GC-induced degradation when analyzed without derivatization.[11] Another report 
complementing the analytical data related to bk-2C-B is also available.[12]  
Recreational use of bk-2C-X has been reported to be closer to MDMA than those of the 
analogous 2C-X.  Users report that the effects begin within 15-20 minutes and increase over 60-
90 minutes.  The general consensus is that bk-2C-B lasts about 10 hours, noticeably longer than 
2C-B.  Negative effects of snorting include severe burning and purple mucus.  Gastrointestinal 
effects including severe diarrhea are also common.[13]  The few user reports on the forums 
indicate that bk-2C-I also lasts longer, but does not produce as intense a high as bk-2C-I.  
Concerns were expressed about the toxicity of iodine.   
Drugs may be ingested by various routes of administration including ‘smoking.’ The most 
common route of administration associated with ring-substituted phenethylamines is the oral 
route and this appears to apply to bk-2C-B as well although there is some indication however that 
this substance may also be smoked. Mixing bk-2C-B with marijuana, either as a solid dose or 
smoked, has been reported by some users to intensify the effects of both drugs.[14]  
A key concern associated with the conditions encountered during pyrolysis is the formation of 
degradation products that may be formed during smoking and knowledge about the behavior of 
drugs under these harsh conditions provide important information on potential biomarkers and 
toxicity.[15] In the present study, bk-2C-B was subjected to pyrolysis conditions for analysis of 
condensed residues formed after vaporization. Furthermore, the analytical characterization and 
pyrolysis of 2-amino-1-(4-iodo-2,5-dimethoxyphenyl)ethanone hydrochloride(bk-2C-I) (Figure 




A sample of bk-2C-B as the hydrogen chloride salt was obtained as a test purchase from an 
internet vendor and 1-(4-Bromo-2,5-dimethoxyphenyl)-2-bromoethanone (11) and 1-(4-bromo-
2,5-dimethoxyphenyl)ethanone (6) were prepared as reported previously.[11] 1-Bromo-2,5-
dimethoxy-4-methylbenzene (1a), 1,4-dibromo-2,5-dimethoxybenzene (5), and all reagents were 
obtained from Sigma-Aldrich (Arklow, Ireland). A sample of bk-2C-I has been donated by an 
Internet retailer in 2015. 
Syntheses 
1-(4-Bromo-2,5-dimethoxyphenyl)-2-chloroethanone (9) 
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This was prepared via the sulfuryl chloride method previously reported for 2-chloro-1-(4-
methylphenyl)propanone[16] to afford yellow crystals with a 36% yield: m.pt. 116-118 oC; 1H 
NMR (CDCl3) δ 7.28 (s, 1H, Ar-H), 7.26 (s, 1H, Ar-H), 4.79 (s, 2H, CH2), 3.95 (s, 3H, OMe), 
3.92 (s, 3H, OMe); 13C NMR (CDCl3) δ 190.99 (C=O), 153.23 (Ar-C), 150.57 (Ar-C), 123.96 
(Ar-C), 119.04 (Ar-C), 117.44 (Ar-CH), 113.20 (Ar-CH), 56.79 (OMe), 56.47 (OMe), 51.03 
(CH2); HR-ESIMS found m/z 292.9267 (theory [M+H]+ C10H1179Br35ClO3, m/z 292.9575). 
5-(4-Bromo-2,5-dimethoxyphenyl)oxazole (10) 
A mixture of 2-amino-1-(4-bromo-2,5-dimethoxyphenyl)ethanone hydrobromide (177 mg, 0.5 
mmol), p-toluenesulfonic acid (5 mg) and triethyl orthoformate (2 mL) was heated at 140 oC for 
3 h. The volatiles were removed under vacuum and the residue was purified by preparative TLC 
(silica gel; cyclohexane/EtOAc, 1/1) to afford a light brown solid (22 mg, 0.08 mmol, 16%): 1H 
NMR (CDCl3) δ 9.06 (s, 1H, O-CH=N), 7.63 (s, 1H, C=CH-N), 7.21 (s, 1H, Ar-H), 7.20 (s, 1H, 
Ar-H), 3.95 (s, 3H, OMe), 3.93 (s, 3H, OMe); 13C NMR (CDCl3) δ 156.28 (O-CH=N), 150.23 
(Ar-C), 149.96 (Ar-C), 138.49 (Ar-C-O), 117.85 (C=CH-N), 116.51 (Ar-CH), 116.22 (Ar-CH), 
108.90 (Ar-C), 106.95 (Ar-C), 56.90 (OMe), 56.17 (OMe). HR-ESIMS found m/z 283.9926 
(theory [M+H]+ C11H1179BrNO3, m/z 283.9917). 
1-Bromo-4-ethyl-2,5-dimethoxybenzene (2) 
Triethylsilane (351 µL, 2.2 mmol) was added to a solution of 1-(4-bromo-2,5-
dimethoxyphenyl)ethanone (259 mg, 1 mmol) in trifluoroacetic acid (2 mL) and the mixture was 
stirred at room temperature for 1 h. The volatiles were removed under vacuum and the residue 
was purified by preparative TLC (silica gel; cyclohexane/EtOAc, 7/3) to afford a colorless solid 
(61 mg, 0.25 mmol, 25%): m.pt. 34-36oC; 1H NMR (CDCl3) δ 7.03 (s, 1H, Ar-H), 6.78 (s, 1H, 
Ar-H), 3.87 (s, 3H, OMe), 3.80 (s, 3H, OMe), 2.62 (q, J = 7.5 Hz, 2H, CH2), 1.20 (t, J = 7.5 Hz, 
3H, CH3); 13C NMR (CDCl3) δ 151.69 (Ar-C), 149.80 (Ar-C), 132.88 (Ar-C), 115.55 (Ar-CH), 
113.63 (Ar-CH), 108.02 (Ar-C), 56.86 (OMe), 55.96 (OMe), 23.25 (CH2), 14.00 (CH3). For this 
compound, sufficient ionization under the employed HR-ESI-MS conditions was not observed 
for high accuracy mass analysis. 
1-Bromo-4-(2-bromoethyl)-2,5-dimethoxybenzene (8) 
A mixture of 2-(4-bromo-2,5-dimethoxyphenyl)ethanol (130 mg, 0.5 mmol, prepared by the 
reduction of 2-(4-bromo-2,5-dimethoxyphenyl)acetic acid with borane-THF) and thionyl 
bromide (2 mL) was refluxed for 2 h. The volatiles were removed under vacuum and the residue 
was recrystallized from cyclohexane/ethyl acetate to afford a beige solid (126 mg, 0.39 mmol, 
78%): m.pt. 66-68 oC; 1H NMR (CDCl3) δ 7.06 (s, 1H, Ar-H), 6.78 (s, 1H, Ar-H), 3.88 (s, 3H, 
OMe), 3.81 (s, 3H, OMe), 3.57 (t, J = 7.5 Hz, 2H, CH2), 3.14 (t, J = 7.5 Hz, 2H, CH2); 13C NMR 
(CDCl3) δ 151.72 (Ar-C), 149.69 (Ar-C), 127.02 (Ar-C), 115.71 (Ar-CH), 115.01 (Ar-CH), 
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109.83 (Ar-C),  56.85 (OMe), 55.86 (OMe), 34.39 (CH2), 31.51 (CH2). For this compound, 
sufficient ionization under the employed HR-ESI-MS conditions was not observed for high 
accuracy mass analysis. 
1-Bromo-4-(2-chloroethyl)-2,5-dimethoxybenzene (7) 
A mixture of 2-(4-bromo-2,5-dimethoxyphenyl)ethanol (130 mg, 0.5 mmol, prepared by the 
reduction of 2-(4-bromo-2,5-dimethoxyphenyl)acetic acid with borane-THF) and thionyl 
chloride (2 mL) was refluxed for 2 h. The volatiles were removed under vacuum and the residue 
was recrystallized from cyclohexane/ethyl acetate to afford colorless solid (89 mg, 0.32 mmol, 
64%): m.pt. 52-54oC; 1H NMR (CDCl3) δ 7.06 (s, 1H, Ar-H), 6.79 (s, 1H, Ar-H), 3.88 (s, 3H, 
OMe), 3.81 (s, 3H, OMe), 3.72 (t, J = 7.5 Hz, 2H, CH2), 3.06 (t, J = 7.5 Hz, 2H, CH2); 13C NMR 
(CDCl3) δ 151.83 (Ar-C), 149.97 (Ar-C), 124.22 (Ar-C), 115.86 (Ar-CH), 115.31 (Ar-CH), 
110.26 (Ar-C), 57.01 (OMe), 56.04 (OMe), 43.46 (CH2), 30.33 (CH2). For this compound, 
sufficient ionization under the employed HR-ESI-MS conditions was not observed for high 
accuracy mass analysis. 
1-Bromo-2,5-dimethoxy-4-vinylbenzene (3) 
Sodium hydride (180 mg, 7.5 mmol) was added to methyltriphenylphosphonium bromide (1.34, 
3.75 mmol) in diethyl ether (25 mL) at 0 °C and the mixture was stirred for 1 h. 4-Bromo-2,5-
dimethoxybenzaldehyde (612 mg, 2.5 mmol) in diethyl ether (10 mL) was then added and the 
mixture was stirred for 3 h at room temperature.  Saturated aqueous sodium carbonate was then 
added, the organic layer collected, dried (anhydrous magnesium sulfate), evaporated to dryness 
and purified by preparative TLC (silica gel; cyclohexane/EtOAc, 7/3) to afford a colorless solid 
(178 mg, 0.73 mmol, 29%): m.pt. 50-52 oC; 1H NMR (CDCl3) δ 7.09 (s, 1H, Ar-H), 7.04 (s, 1H, 
Ar-H), 6.99 (dd, J = 17.7, 11.2 Hz, 1H, =CH) 5.76 (dd, J = 17.7, 1.1 Hz, 1H, one H from =CH2), 
5.33 (dd, J = 11.2, 1.1 Hz, 1H, one H from =CH2), 3.90 (s, 3H, OMe) and 3.82 (s, 3H, OMe); 13C 
NMR (CDCl3) δ 151.11 (Ar-C), 150.04 (Ar-C), 130.86 (=CH), 126.53 (Ar-C), 116.49 (Ar-CH), 
114.83 (Ar-CH), 110.99 (Ar-C), 110.03 (=CH2), 56.75 (OMe) and 55.23 (OMe); HR-ESIMS 
found m/z 243.0020 (theory [M+H]+ C10H1279BrO2, m/z 243.0015).  
Instrumentation 
All samples were run on an Agilent Technologies gas chromatograph-mass spectrometer (6890 
N GC and 5975 inert mass selective detector) fitted with a DB-5 MS column (30 m x 0.25 mm, 
0.25 µm film thickness) with the following parameters: injector port, 260 °C, transfer line, 250 
°C; EI, 70 eV; TIC mode, m/z 35-550; ionization source, 230 °C; quadrupole, 150 °C. Helium 
was used as the carrier gas (1.1 mL/min). The temperature program started at 100 °C with a ramp 
rate of 15 °C per minute up to 300 °C followed by a 34.7 min hold for a total run time of 48 min.  
The solvent delay was set for 4 min.  
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NMR spectra 1H (600 MHz) and 13C (150 MHz) were recorded on a Bruker AV600 NMR 
spectrometer using a 5 mm TCI cryoprobe.  
HR-ESI mass spectra were recorded by direct injection into a LTQ Orbitrap Discovery (Thermo 
Fisher, UK). Samples were dissolved in acetonitrile/water (1:1, containing 0.1% formic acid) and 
infused at a rate of 5 µl/min. Full accurate high-resolution (30000) mass scans were performed in 
positive electrospray mode. Measured accurate masses were within ± 5ppm of the theoretical 
masses. The following conditions were used: drying gas (N2) 10L/min, capillary temperature 310  
oC, spray voltage 4 V, capillary voltage 22 V and tube lens 77 V. 
Pyrolysis 
A sample of the drug (5-9 mg) was loaded into an aluminum foil boat, placed in the bottom of a 
20 mL crimp vial and heated with a disposable lighter for approximately 30 s until yellow vapors 
formed in the vial and a brown tar had formed in the boat. The foil cup was removed and the 
flask was rinsed with 1 mL of acetonitrile to dissolve the residues for GC-MS analysis. 
Acetylation was performed using 100 µL of acetic anhydride and heating at 70 °C for 3 h.  The 
vial was cooled to room temperature and the contents analyzed by GC-MS. For TMS 
derivatization, the residue was taken up in N,O-bis(trimethylsilyl)trifluoroacetamide 
(BSTFA)/toluene (1/1) and analyzed by GC-MS. Ethylation was performed by dissolving the 
residue in acetone (200 µL). Iodoethane (50 µL) and anhydrous potassium carbonate (approx. 20 
mg) were added and the mixture was heated at 90 oC for 20 min. The mixture was allowed to 
cool to room temperature, evaporated to dryness and the residue was reconstituted in acetonitrile 
(200 µL) for GC-MS analysis. For NMR studies, 100 mg of bk-2C-B was pyrolyzed in a similar 
manner, using a 500 mL round bottom flask. The pyrolysate was dissolved in deuterated 
chloroform.  
RESULTS AND DISCUSSION 
The bk-2C-B and bk-2C-I were both obtained from online vendors. The identity of the bk-2C-B 
was confirmed in a previous study.[11]  While analysis by LC-MS and NMR indicated the sample 
was not contaminated with by-products or adulterants, 1-(4-bromo-2,5-
dimethoxyphenyl)ethanone and a pyrazine dimer were detected when the sample was run on GC-
MS without derivatization. A potential reason for this formation might have included a catalytic 
conversion in the injection port liner due to the presence of active sites, which suggests that the 
extent of product formation might potentially vary across GC systems.  In addition, it was 
determined that the purchased bk-2C-B was composed of mixture of chloride and bromide salts.   
The GC-MS of the bk-2C-B and bk-2C-I are shown in Figure 2.  In addition to 1-(4-bromo-2,5-
dimethoxyphenyl)ethanone and the pyrazine dimer reported by Power et al.[11], 5-(4-bromo-2,5-
dimethoxyphenyl)oxazole was formed upon injection of the bk-2C-B on the GC.  Whereas both 
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1-(4-iodo-2,5-dimethoxyphenyl)ethanone and 5-(4-iodo-2,5-dimethoxyphenyl)oxazole were 
present in the chromatogram of the bk-2C-I, the iodo dimer was not detected. 
Pyrolysis products of bk-2C-B products were produced under conditions comparable to those 
employed by drug users using a ‘meth pipe’.[15] The sample was heated with a butane lighter 
until yellow fumes appeared and an orange residue was deposited on the sides of the glass vial.  
The pyrolysis was repeated several times in order to determine which product were 
representative of those inhaled under the conditions used in drug abuse.  A final pyrolysis was 
run with 9 mg in order to obtain sufficient product for the interpretation of the mass spectra.  The 
substances reported here appeared in multiple pyrolysis runs. 
Twelve pyrolysis products, shown in Figure 3, were identified through interpretation of the mass 
spectra and confirmed by comparison to synthesized standards.  The chromatograms of the 
pyrolates, standards and mass spectra for products (1a)-(5) are shown in Figure 4. Interpretation 
of the mass spectra for products (6)-(12) are shown in Figure 5 was aided by the characteristic 
isotope patterns of bromine and chlorine (Supporting Information).  
The stability of the enol radical resulted in a distribution of products from homolytic reactions.  
Most of the pyrolysis products underwent homolytic cleavage of the C-N, although some C-C 
bond cleavage was observed.  The mechanism for the hemolytic cleavage is shown in Figure 6. 
The stereochemistry of the halogen addition also supports a hemolysis.  Products (1a), (1b), (2), 
(3), (5), (7) and (8) also lost the beta ketone. The first peak detected at 6.18 min revealed co-
elution of two pyrolates. One, 1-bromo-2,5-dimethoxy-4-methylbenzene (1a), was an example of 
beta C-O bond cleavage. The second was consistent with one or both of the phenols, 3-bromo-4-
methoxyphenol and 2-bromo-4-methoxyphenol (1b), which illustrated activity at the benzene 
ring, resulting in both C-C cleavage and demethylation of the methoxy group.  In comparison, 
the C-C cleavage was not observed in the pyrolysis of mephdrone.[17] The phenols were 
confirmed by derivatization with acetic anhydride where a gain in mass of 42 amu resulted in a 
retention time shift to 6.75 min. The mass spectrum of the derivatized phenol is shown in Figure 
5.  
The formation of 1-bromo-4-ethyl-2,5-dimethoxy-benzene (2) was an example of deamination, 
as well as loss of the loss of oxygen in the ketone. The mechanism might have been similar to the 
formation of iso-mephedrone observed during mephedrone pyrolysis, with the formation of a 
cyclic amine intermediate that would result in the formation of an iso-2C-B intermediate, 
followed by deamination.[16]  The peak eluting at 7.01 min was confirmed as 1-bromo-4-ethenyl-
2,5-dimethoxy-benzene (3) 
The fragmentation pattern representing the peak at 7.38 min was initially thought to represent 4-
bromo-2,5-dimethoxy-benzaldehyde but this was not confirmed when compared to a standard.  
Instead, an alternative structure was proposed, 1-(4-bromo-2-hydroxy-5-
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methoxyphenyl)ethanone (4), which was confirmed by comparison with a standard and by NMR 
provided in the Supplemental Information. Other pyrolysis products that retained the ketone 
group included pyrolates (6), (9), and (11). 1-(4-Bromo-2,5-dimethoxyphenyl)ethanone was 
formed by loss of the amine group, also seen in the pyrolysis of mephedrone.[16] In mephedrone, 
however, halogen substitution similar to 1-(4-bromo-2,5-dimethoxyphenyl)-2-chloro-ethanone 
(9) or 2-bromo-1-(4-bromo-2,5-dimethoxyphenyl)-ethanone (11) was not detected.  In the later 
example, chlorination rather than bromination would occur in the case of mephedrone. Of the 
remaining products, (5), (7) and (8) were halogenated analogs of (1a), and (2). Two halogenated 
products were detected in the pyrolysis of mephedrone and identified as α-chloro ketones, 1-
chloro-1-(4-methylphenyl)- 2-propanone and 2-chloro-1-(4-methylphenyl)-1-propanone[16]. 
The pyrolysis products of bk-2C-B differed significantly from those observed with other 
phenethylamines[15] including methiopropamine and the ring-substituted cathinone, 
mephedrone.[15,16] Methylation[18] and N,O rearrangement did not occur.[19] Product (1b) was 
unique in that the C-C bond cleavage appeared to occur at the benzene ring and the 
corresponding product was not detected in either the pyrolysis of methamphetamine or 
mephedrone.[16,18] The (1b) and (4) represented reactions at the benzene ring, presumably 
through the formation of an alcohol from the associated methoxy group.  Products (5), (7-9), and 
(11) were the result of halogenation.  Several products resulted from bond cleavage of either the 
α-β C-C bond (1a) or the C-N bond (2-4, 6) and similar products were detected in the pyrolysis 
of both methamphetamine and methiopropamine.[17,18] Products (1a, 2, and 3) were analogous to 
the oxidative degradation products reported for methamphetamine.[18]  
Only two products retained the amine nitrogen: 5-(4-bromo-2,5-dimethoxyphenyl)oxazole (10) 
and a dimer (12). These substances were present in the chromatograms of bk-2C-B as received 
and may be formed either during the pyrolysis or in the GC injector by a reaction of bk-2C-B as 
reported by Power et al.[11] A proposed mechanism for the fragmentation of product (10) is 
shown in Figure 7, with formaldehyde being formed in-situ from breakdown of the bk-2C-B.  
Formation of the pyrazine dimer (12) may have formed through a condensation reaction of the β-
ketone as seen in the report by Powers et al., although thermal rearrangements were also 
observed during mephedrone and methiopropamine pyrolysis.[16,17]  
The difference in the products may have reflected the activating nature of the methoxy groups 
located on the benzene ring.  Several products originating from oxidative degradation or bond 
cleavage showed a halogenated counterpart: compounds (7) and (8) were the chlorinated and 
brominated counterparts of (2). Products (9 and 11) were the halogenated counterparts of (6). 
The halogenated counterparts for the phenols (1b and 4) were not detected. 
While some level of toxicity is predicted for the α-chloro ketones,[20] no toxicity data are 
available for the substances formed during bk-2C-B pyrolysis. Products (1a, 2, and 5) have been 
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studied as fungicides.[21] The ethenyl compound (3) has been researched for activity as a 2-
photon chromophore.[22]  Products (6 and 11) were used as precursors in the preparation of 
serotonin 5-HT2A receptor agonists[10] and (1b) was identified as a precursor for 1,2-cyclized 
phenylethylamines studied as agonists for both 5-HT2A and 5-HT2B receptors.[23] A literature 
structure search for product (7) gave no results, whereas the analogous bromoethyl product (8) 
appeared in a study of phenylethylamine analogs for use in treating glaucoma.[24] 
As summarized in the Supporting Information, similar products were identified following the 
pyrolysis of bk-2C-I. The retention times increased as a reflection of increased mass of the iodine 
substituent.  Products analogous to bk-2C-B (1-4), (6-8) and (10) were also formed during the 
pyrolysis of bk-2C-I.  Two additional pyrolysis products were detected and tentatively identified 
through interpretation of their EI mass spectra.  1-(2,5-Dimethoxyphenyl)-ethanone (13) might 
have been formed by cleavage at the nitrogen and the decomposition product 1-iodo-4-ethenyl-5-
methoxyphenol (14) might have been a decomposition product similar to 1-iodo-4-ethenyl-2,5-
dimethoxy-benzene (3) and 1-(4-iodo-2-hydroxy-5-methoxyphenyl)-ethanone (4). The only bk-
2C-I pyrolysis product mentioned in a biological study was the product (4) mentioned in a patent 
for P2X3 and P2X2/3 antagonists.[25] 
Conclusion 
Inhalation of a vaporized drug commonly produces a quick onset of effects but also shorter 
duration. However, the potential ingestion of pyrolysis products with unknown toxicity adds an 
element of concern. Twelve products resulting from the pyrolysis of bk-2C-B have been 
identified and similar chemicals were detected for bk-2C-I. The pyrolysis conditions resulted 
primarily in oxidative degradation and C-C or N-C bond cleavage, often accompanied by 
halogenation. 
Acknowledgments 
Funding for this study was provided by the National Science Foundation’s Research Experiences 
for Undergraduates Program (Award #1261322). The authors thank the Internet vendor for the 
donation of the bk-2C-I sample. 
Page 10 of 19
http://mc.manuscriptcentral.com/dta



































































[1] A.T. Shulgin, T. Manning, P.F. Daley, The Shulgin Index - Volume One: Psychedelic 
Phenethylamines and Related Compounds, Transform Press, Berkeley, CA, USA, 2011. 
[2] A. Shulgin, A.T. Shulgin, Phenethylamines I Have Known and Loved: A Chemical Love 
Story, Transform Press, Berkeley, CA, USA, 1991. 
[3] L.A. King. New phenethylamines in Europe. Drug Test. Anal. 2014, 6, 808. 
[4] S.D. Brandt, L.A. King, M. Evans-Brown. The new drug phenomenon. Drug Test. Anal. 
2014, 6, 587. 
[5] United Nations Office on Drugs and Crime (UNODC). The challenge of new 
psychoactive substances. A Report from the Global SMART Programme March 2013. United 
Nations Publication, Vienna, 2013. Available at: 
https://www.unodc.org/documents/scientific/NPS_2013_SMART.pdf [18 September 2016]. 
[6] European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Drug 
Report 2016: Trends and Developments. EMCDDA, Lisbon, 2016. Available at: 
http://www.emcdda.europa.eu/system/files/publications/2637/TDAT16001ENN.pdf [09 
September 2016]. 
[7] M. Evans-Brown, R. Sedefov. New psychoactive substances: driving greater complexity 
into the drug problem. Addiction 2017, 112, 36. 
[8] European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)-Europol. 
Europol 2013 Annual Report on the implementation of Council Decision 2005/387/JHA. 
EMCDDA, Lisbon, 2014. Available at: 
http://www.emcdda.europa.eu/system/files/publications/814/TDAN14001ENN_475519.pdf [18 
September 2016]. 
[9] S. Odoardi, F.S. Romolo, S. Strano-Rossi. A snapshot on NPS in Italy: distribution of 
drugs in seized materials analysed in an Italian forensic laboratory in the period 2013-2015. 
Forensic Sci. Int. 2016, 265, 116. 
[10] R.A. Glennon, M.L. Bondarev, N. Khorana, R. Young. β-Oxygenated analogues of the 5-
HT2A serotonin receptor agonist 1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane. J. Med. 
Chem. 2004, 47, 6034. 
[11] J.D. Power, P. Kavanagh, J. O'Brien, M. Barry, B. Twamley, B. Talbot, G. Dowling, S.D. 
Brandt. Test purchase, identification and synthesis of 2-amino-1-(4-bromo-2, 5-
dimethoxyphenyl)ethan-1-one (bk-2C-B). Drug Test. Anal. 2015, 7, 512. 
[12] G. Frison, S. Odoardi, S. Frasson, R. Sciarrone, G. Ortar, F.S. Romolo, S. Strano Rossi. 
Characterization of the designer drug bk-2C-B (2-amino-1-(bromo-dimethoxyphenyl)ethan-1-
one) by gas chromatography/mass spectrometry without and with derivatization with 2,2,2-
Page 11 of 19
http://mc.manuscriptcentral.com/dta


































































trichloroethyl chloroformate, liquid chromatography/high-resolution mass spectrometry, and 
nuclear magnetic resonance. Rapid Commun. Mass Spectrom. 2015, 29, 1196. 
[13] Drugs-Forum bk-2C-B Drug Info. https://drugs-
forum.com/forum/showthread.php?t=228051 [ 09 January 2017]. 
[14] http://www.rollitup.org/t/bk-2c-b-thread.824039/  [ 09 January 2017]. 
[15] S. Bell, C. Nida. Pyrolysis of drugs of abuse: a comprehensive review. Drug Test. Anal. 
2015, 7, 445. 
[16] P. Kavanagh, J. O'Brien, J.D. Power, B. Talbot, S.D. McDermott. 'Smoking' mephedrone: 
the identification of the pyrolysis products of 4-methylmethcathinone hydrochloride. Drug Test. 
Anal. 2013, 5, 291. 
[17] E.D. Bouso, E.A. Gardner, J.E. O'Brien, B. Talbot, P.V. Kavanagh. Characterization of 
the pyrolysis products of methiopropamine. Drug Test. Anal. 2014, 6, 676. 
[18] M. Sato, M. Hida, H. Nagase. Analysis of pyrolysis products of methamphetamine. J. 
Anal. Toxicol. 2004, 28, 638. 
[19] C.L. Stevens, R.D. Elliott, B.L. Winch. Aminoketone rearrangements. II. The 
rearrangement of phenyl α-aminoketones. J. Am. Chem. Soc. 1963, 85, 1464. 
[20] A.K. Nigam, M.V. Suryanarayana, P.K. Gutch, S.P. Sharma, L.N. Tomar, R. 
Vijayaraghavan. Thermal decomposition studies of riot control agent ω-chloroacetophenone 
(CN) by pyrolysis-gas chromatography-mass spectrometry. J. Hazard Mater. 2010, 184, 506. 
[21] R.M. Scribner, E.J. Soboszenski. Bodenfungicid. DE1274398. E. I. du Pont de Nemours 
and Company, Wilimgton, Delaware, USA. 1968. 
[22] K. Kamada, Y. Iwase, K. Sakai, K. Kondo, K. Ohta. Cationic two-photon absorption 
chromophores with double-and triple-bond cores in symmetric/asymmetric arrangements. J. 
Phys. Chem. C 2009, 113, 11469. 
[23] V. Isberg, J. Paine, S. Leth-Petersen, J.L. Kristensen, D.E. Gloriam. Structure-activity 
relationships of constrained phenylethylamine ligands for the serotonin 5-HT2 receptors. Plos 
One 2013, 8, e78515. 
[24] M. Hellberg, A. Namil, Z. Feng, J. Ward. Phenylethylamine analogs and their use for 
treating glaucoma. US 2007/0072920 A1. Alcon Research Ltd. Fort Worth, Texas, USA. 2007. 
[25] C. Broka, D. Carter, M. Dillon, R. Hawley, A. Jahangir, C. Lin, D. Parish. 
Diaminopyrimidines as P2X3 and P2X2/3 antagonists. US2005/0209260 A1. Roche Palo Alto 
LLC, Palo Alto, CA, USA. 2005. 
  
Page 12 of 19
http://mc.manuscriptcentral.com/dta



































































Figure 1. Chemical structures of 2-(4-bromo-2,5-dimethoxyphenyl)ethan-1-amine hydrochloride 
(2C-B), 2-amino-1-(4-bromo-2,5-dimethoxyphenyl)ethanone hydrochloride (bk-2C-B), and 2-
amino-1-(4-iodo-2,5-dimethoxyphenyl)ethanone hydrochloride(bk-2C-I) respectively. 
Figure 2.  Chromatograms of a. bk-2C-B and b. bk-2C-I. 
Figure 3.  Schematic of bk-2C-B pyrolysis products. 
Figure 4.  (a) Total ion chromatogram for pyrolysis products of 2-amino-1-(4-bromo-2,5-
dimethoxyphenethyl)ethanone chloride (bk-2C-B); (b) comparison with standards; and (c) mass 
spectra for products (1a)-(5).  
Figure 5.  Electron ionization mass spectra of the products (6)-(12) formed during pyrolysis of 
2-amino-1- (4-bromo-2,5-dimethoxyphenethyl)ethanone hydrochloride (bk-2C-B). 
Figure 6.  Schematic of the hemolytic cleavage of bk-2C-Br. 
Figure 7.  Proposed mechanism for the fragmentation of product 10. 
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FIgure 1.  Chemical structures of 2-(4-bromo-2,5-dimethoxyphenyl)ethan-1-amine hydrochloride (2C-B), 2-
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Figure 2.  Chromatograms of a. bk-2C-B and b. bk-2C-I.  
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Figure 3.  Schematic of bk-2C-B pyrolysis products.  
Figure 3  
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Figure 4.  (a) Total ion chromatogram for pyrolysis products of 2-amino-1-(4-bromo-2,5-
dimethoxyphenethyl)ethanone chloride (bk-2C-B); (b) comparison with standards; and (c) mass spectra for 
products (1a)-(5).  
Figure 4  
290x450mm (300 x 300 DPI)  
 
 
Page 17 of 19
http://mc.manuscriptcentral.com/dta

































































Figure 5.  Electron ionization mass spectra of the products (6)-(12) formed during pyrolysis of 2-amino-1- 
(4-bromo-2,5-dimethoxyphenethyl)ethanone hydrochloride (bk-2C-B).  
Figure 5  
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Figure 6.  Schematic of the hemolytic cleavage of bk-2C-Br.  
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Figure 7.  Proposed mechanism for the fragmentation of product 10.  
Figure 7  
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